ATE16565T1 - Pharmazeutische orale verabreichungsformen eines aktiven wirkstoffes, geeignet zum bilden oder freisetzen von bicarbonationen. - Google Patents

Pharmazeutische orale verabreichungsformen eines aktiven wirkstoffes, geeignet zum bilden oder freisetzen von bicarbonationen.

Info

Publication number
ATE16565T1
ATE16565T1 AT81107236T AT81107236T ATE16565T1 AT E16565 T1 ATE16565 T1 AT E16565T1 AT 81107236 T AT81107236 T AT 81107236T AT 81107236 T AT81107236 T AT 81107236T AT E16565 T1 ATE16565 T1 AT E16565T1
Authority
AT
Austria
Prior art keywords
dosage forms
oral dosage
active substance
bicarbonation
releasing
Prior art date
Application number
AT81107236T
Other languages
English (en)
Inventor
Joachim Dr Med Vet Helbig
Klaus F Dr Kopp
Original Assignee
Olima Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8187910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE16565(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Olima Holding Ag filed Critical Olima Holding Ag
Application granted granted Critical
Publication of ATE16565T1 publication Critical patent/ATE16565T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT81107236T 1981-09-14 1981-09-14 Pharmazeutische orale verabreichungsformen eines aktiven wirkstoffes, geeignet zum bilden oder freisetzen von bicarbonationen. ATE16565T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP81107236A EP0074426B1 (de) 1981-09-14 1981-09-14 Pharmazeutische orale Verabreichungsformen eines aktiven Wirkstoffes, geeignet zum Bilden oder Freisetzen von Bicarbonationen

Publications (1)

Publication Number Publication Date
ATE16565T1 true ATE16565T1 (de) 1985-12-15

Family

ID=8187910

Family Applications (1)

Application Number Title Priority Date Filing Date
AT81107236T ATE16565T1 (de) 1981-09-14 1981-09-14 Pharmazeutische orale verabreichungsformen eines aktiven wirkstoffes, geeignet zum bilden oder freisetzen von bicarbonationen.

Country Status (5)

Country Link
EP (1) EP0074426B1 (de)
AT (1) ATE16565T1 (de)
AU (1) AU551361B2 (de)
DE (1) DE3173007D1 (de)
WO (1) WO1983001570A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759586A (en) * 1996-07-19 1998-06-02 Fuchs; Norbert Pharmaceutical or dietetic composition

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2130087A (en) * 1982-09-22 1984-05-31 Dr Joachime Helbig Pharmaceutical oral dosage forms of an active agent capable of forming or releasing bicarbonate ions
ATE135915T1 (de) * 1991-01-26 1996-04-15 Senju Pharma Co Mittel zur zersetzung von gallensteinen
FR2687291B1 (fr) * 1992-02-17 1994-06-03 Sfbd Vivis Aliment pour sportif et son procede de fabrication.
KR20090004886A (ko) * 2006-02-28 2009-01-12 데이빗 알. 비먼 물 구성물
EP1970066A1 (de) * 2007-03-12 2008-09-17 Medice Arzneimittel Pütter GmbH & Co. KG Pharmazeutische Zusammensetzung zur Behandlung einer Übersäuerung des Blutes
EP2072046A1 (de) * 2007-12-21 2009-06-24 K.F. Prof. Dr. Kopp Verwendung einer hydrocarbonathaltigen Zubereitung zur Prävention oder Behandlung von Herz-Kreislauf-Erkrankungen, Diabetes, Osteoporose und chronischem Nierenversagen
DE102010043318A1 (de) 2010-11-03 2012-05-03 Klaus F. Kopp Calciumcarbonat enthaltende Zusammensetzung
EP2545788A1 (de) * 2011-07-13 2013-01-16 Martin Hulliger Diätisches Mehrkomponentensystem

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE287292C (de) *
FR1272923A (fr) * 1959-03-13 1961-10-06 Professeur Jack Masquelier Mode de fabrication de comprimés
AU1039170A (en) * 1969-02-24 1971-07-22 Abbott Laboratories Tableting medium
DE2406625C3 (de) * 1973-02-27 1979-11-08 Zenyaku Kogyo K.K., Tokio Verfahren zum Überziehen von festen Teilchen mit einem im Verdauungstrakt löslichen Film und Vorrichtung zu seiner Durchführung
US4289750A (en) * 1978-10-16 1981-09-15 Kopp Klaus F Therapy of conditions which may be associated with altered renal function and dosage forms therefor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759586A (en) * 1996-07-19 1998-06-02 Fuchs; Norbert Pharmaceutical or dietetic composition

Also Published As

Publication number Publication date
EP0074426B1 (de) 1985-11-21
WO1983001570A1 (fr) 1983-05-11
AU551361B2 (en) 1986-04-24
DE3173007D1 (en) 1986-01-02
EP0074426A1 (de) 1983-03-23

Similar Documents

Publication Publication Date Title
PT751781E (pt) Utilizacao de anticorpos monoclonais ou ligandos oligomericos soluveis no fabrico de um medicamento para a prevencao ou tratamento de desordens neoplasicas
FI833605A0 (fi) Ny oral mopidamolprodukt
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
ATE251140T1 (de) N-(2 oxoacetyl oder sulphonyl)- pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
HU907065D0 (en) Process for manufacturing pharmaceutical preparative of transdermal action containing 2-amino-6-(n-propyl-amino)-4,5,6,7-tetrahydro-benzothiazole
DE69435086D1 (de) Phenylacetate und Derivate, allein oder in Kombination mit anderen Verbindungen, zur Behandlung von neoplastischen und anderen Erkrankungen
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
NO972475L (no) Ny antitrombotisk formulering, fremgangsmåte for dens fremstilling og anvendelse derav
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ES482097A1 (es) Procedimiento para preparar derivados acilicos de carnitina.
DK71387A (da) Terapeutisk middel til behandling af psoriasis
ATE16565T1 (de) Pharmazeutische orale verabreichungsformen eines aktiven wirkstoffes, geeignet zum bilden oder freisetzen von bicarbonationen.
DE3584560D1 (de) Arzneimittelzusammensetzung geeignet zur behandlung oder prophylaxe von herzstoerungen.
DE69426471D1 (de) Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie
DK412788D0 (da) Farmaceutisk middel til brug ved behandling af uraemi
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
NO801387L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive morfantridin-derivater
NO830527L (no) Analogifremgangsmaate for fremstilling av 2,3-diaryl-5-halogenthiofener
DE58903964D1 (de) Fluessige orale formulierung.
NO156900C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater.
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
Arató et al. Reduced plasma cyclic AMP level during prophylactic lithium treatment in patients with affective disorders.
DE3378979D1 (en) 1-acyl-3-pyridylmethylguanidines and their use as antihypertensive agents
SE9000207L (sv) Laekemedel samt anvaendningen av detsamma

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee